Definium Therapeutics (DFTX) Return on Invested Capital (2022)

Definium Therapeutics (DFTX) reported Return on Invested Capital of 0.0% for Q3 2022, little changed quarter-over-quarter from 0.0% in Q2 2022.

Definium Therapeutics (DFTX) Return on Invested Capital (2022) Analysis & Trends

Definium Therapeutics (DFTX) has 1 years of Return on Invested Capital data on file, last reported at 0.0% in Q3 2022.

  • Return on Invested Capital for Q3 2022 came in at 0.0%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was 0.0% (changed N/A YoY), and the FY2021 annual result was 0.0%, changed N/A from the prior year.
  • Return on Invested Capital was little changed at 0.0% in Q3 2022 per DFTX's latest filing, from 0.0% in the prior quarter.
  • Over five years, Return on Invested Capital peaked at 0.0% in Q2 2022 and troughed at 0.0% in Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROIC (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.01%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -0.01%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -0.01%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 0.00%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Definium Therapeutics 2.46 Bn 2.09 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2022 0.00%
Jun 30, 2022 0.00%